Matthias Oelke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthias Oelke has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Lars Viktrup
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
5 shared publicationsCharalampos Mamoulakis
Department of Urology, University of Crete Medical School, Heraklion, Crete, Greece
4 shared publicationsDavid Cox
Eli Lilly and Company
4 shared publicationsRichard Berges
Pan-Klinik
4 shared publicationsGommert A. van Koeveringe
Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands
3 shared publicationsK. Dreikorn
Urologische Praxis, Bremen, Deutschland
3 shared publications
Latest Publications
- 20 September 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (6) , e2665-e2667
Training effects during simulation of robot de-docking for cardiac resuscitation
- 20 September 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (6) , e2665-e2667
Training effects during simulation of robot de-docking for cardiac resuscitation
- 22 January 2017
- Published by Wiley in BJU International
- Vol. 119 (5) , 793-803
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo‐controlled clinical studies
Objective: To assess efficacy and safety of tadalafil in men aged ≥75 years with lower urinary tract symptoms associated with benign prostatic hyperplasia ( LUTS / BPH ) and additional safety in men aged ≥75 years with erectile dysfunction ( ED ). Patients and Methods: We conducted an integrated analysis of 12 phase II – III randomized, double‐blind and/or open‐label extension studies to evaluate short‐term (12–26 weeks) efficacy and short‐ and longer‐term (42–52 weeks) safety in men aged P = 0.034). Tadalafil was not statistically significantly better than placebo in men aged ≥75 years, but effect size varied between studies. Maintenance of efficacy with tadalafil was observed across age groups. Short‐term tadalafil safety findings for men aged <75 vs ≥75 years included: TEAE s (52 [33.8%] vs 503 [30.1%]), AE s leading to discontinuation (3 [1.9%] vs 50 [3.0%]), SAE s (4 [2.6%] vs 15 [0.9%]) and cardiovascular AE s (4 [2.6%] vs 30 [1.8%]). Long‐term tadalafil safety data did not reveal clinically relevant differences between age groups. Limitations include exclusion of men with serious co‐existing conditions and limited sample sizes of men aged ≥75 years. Conclusions: Efficacy with once‐daily tadalafil 5 mg in the treatment of LUTS / BPH differed between men aged <75 vs ≥75 years, with significant efficacy in the <75‐year age group. The older age group had more concomitant diseases and used more drugs, which may have reduced efficacy. The small sample size precluded uni‐/multivariate analyses to assess plausible interference from confounding factors. Tadalafil had a reassuring safety profile and no evidence of increased cardiovascular AE s in aging men.
- 22 January 2017
- Published by Wiley in BJU International
- Vol. 119 (5) , 793-803
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo‐controlled clinical studies
Objective: To assess efficacy and safety of tadalafil in men aged ≥75 years with lower urinary tract symptoms associated with benign prostatic hyperplasia ( LUTS / BPH ) and additional safety in men aged ≥75 years with erectile dysfunction ( ED ). Patients and Methods: We conducted an integrated analysis of 12 phase II – III randomized, double‐blind and/or open‐label extension studies to evaluate short‐term (12–26 weeks) efficacy and short‐ and longer‐term (42–52 weeks) safety in men aged P = 0.034). Tadalafil was not statistically significantly better than placebo in men aged ≥75 years, but effect size varied between studies. Maintenance of efficacy with tadalafil was observed across age groups. Short‐term tadalafil safety findings for men aged <75 vs ≥75 years included: TEAE s (52 [33.8%] vs 503 [30.1%]), AE s leading to discontinuation (3 [1.9%] vs 50 [3.0%]), SAE s (4 [2.6%] vs 15 [0.9%]) and cardiovascular AE s (4 [2.6%] vs 30 [1.8%]). Long‐term tadalafil safety data did not reveal clinically relevant differences between age groups. Limitations include exclusion of men with serious co‐existing conditions and limited sample sizes of men aged ≥75 years. Conclusions: Efficacy with once‐daily tadalafil 5 mg in the treatment of LUTS / BPH differed between men aged <75 vs ≥75 years, with significant efficacy in the <75‐year age group. The older age group had more concomitant diseases and used more drugs, which may have reduced efficacy. The small sample size precluded uni‐/multivariate analyses to assess plausible interference from confounding factors. Tadalafil had a reassuring safety profile and no evidence of increased cardiovascular AE s in aging men.
- Open Access
- 17 October 2016
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 70 (11) , 940-949
Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real‐life practice database containing 8659 European and US ‐American patients
The aim of this study was to investigate the quality and timing of the diagnosis and treatment of nocturia in real-life practice in European and US-American patients to obtain better insights into the management of nocturia in different Western healthcare systems. Data were drawn from the “LUTS Disease Specific Programme,” a real-life survey of physicians and patients in France, Germany, Spain, UK and the USA. Physicians completed a patient record form for lower urinary tract symptoms (LUTS) patients. Patients filled out a self-completion form, indicating – among other items – information on the mean number of day- and night-time voids during the last 7 days, and questions on the management of LUTS in daily practice. In total, 8659 patients were analysed. The majority of patients initially consulted a physician because of worsening of LUTS frequency (43%–58%) or severity (44%–55%). Only 37% of all LUTS diagnoses, regardless of the appearance or severity of nocturia, were based on bladder diaries. Patients took approximately 1 year to consult a medical professional following the onset of LUTS. At the initial visit, most patients received advice on behavioural strategies. Regardless the type of LUTS and physician, 59% of men received α-blockers and 76% of women antimuscarinics. Data show that patients with nocturia and LUTS accept their symptoms for a considerable period before they seek help or ultimately receive treatment. They may therefore be enduring significant negative impact on their quality-of-life which could be avoided. Physicians rarely use bladder diaries and primarily use antimuscarinics (women) or α-blockers (men). Improved awareness of nocturia among patients and physicians could improve the management of nocturia.
- 17 October 2016
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 70 (11) , 940-949
Open AccessNocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real‐life practice database containing 8659 European and US ‐American patients
The aim of this study was to investigate the quality and timing of the diagnosis and treatment of nocturia in real-life practice in European and US-American patients to obtain better insights into the management of nocturia in different Western healthcare systems. Data were drawn from the “LUTS Disease Specific Programme,” a real-life survey of physicians and patients in France, Germany, Spain, UK and the USA. Physicians completed a patient record form for lower urinary tract symptoms (LUTS) patients. Patients filled out a self-completion form, indicating – among other items – information on the mean number of day- and night-time voids during the last 7 days, and questions on the management of LUTS in daily practice. In total, 8659 patients were analysed. The majority of patients initially consulted a physician because of worsening of LUTS frequency (43%–58%) or severity (44%–55%). Only 37% of all LUTS diagnoses, regardless of the appearance or severity of nocturia, were based on bladder diaries. Patients took approximately 1 year to consult a medical professional following the onset of LUTS. At the initial visit, most patients received advice on behavioural strategies. Regardless the type of LUTS and physician, 59% of men received α-blockers and 76% of women antimuscarinics. Data show that patients with nocturia and LUTS accept their symptoms for a considerable period before they seek help or ultimately receive treatment. They may therefore be enduring significant negative impact on their quality-of-life which could be avoided. Physicians rarely use bladder diaries and primarily use antimuscarinics (women) or α-blockers (men). Improved awareness of nocturia among patients and physicians could improve the management of nocturia.
- 22 July 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (1) , 153-159
Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men
Purpose Detrusor underactivity (DU) has lately gained increasing interest because this bladder condition is an important cause of post-void residual urine and lower urinary tract symptoms (LUTS) in adult men. Until now, DU can only be diagnosed by pressure–flow measurement. Therefore, the aim of this study was to search for noninvasive tests which can safely predict DU in adult men. Methods Unselected, treatment-naïve male patients aged ≥40 years with uncomplicated, non-neurogenic LUTS were prospectively evaluated. All men received—after standard assessment of male LUTS–ultrasound detrusor wall thickness (DWT) measurements at a bladder filling ≥250 ml and computer urodynamic investigation. DU was defined as incomplete bladder emptying (>30 ml) in the absence of bladder outlet obstruction or dysfunctional voiding. Classification and regression tree (CART) analysis was used to determine parameters and threshold values for DU. Results The study population consisted of 143 consecutive men with medians of 62 years, IPSS 16, and prostate volume 35 ml. In total, 33 patients (23.1 %) had DU. CART analysis showed that all men with DWT ≤ 1.23 mm plus bladder capacity >445 ml had DU. This multivariate model has a sensitivity of 42 %, specificity of 100 %, positive predictive value of 100 %, and negative predictive value of 85 %. Conclusions This study showed that all men with ultrasound DWT ≤ 1.23 mm + bladder capacity >445 ml have DU. Combination of these two tests could help physicians to diagnose DU noninvasively in clinical practice. A prospective independent study should confirm these results.
- 22 July 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (1) , 153-159
Ultrasound detrusor wall thickness measurement in combination with bladder capacity can safely detect detrusor underactivity in adult men
Purpose Detrusor underactivity (DU) has lately gained increasing interest because this bladder condition is an important cause of post-void residual urine and lower urinary tract symptoms (LUTS) in adult men. Until now, DU can only be diagnosed by pressure–flow measurement. Therefore, the aim of this study was to search for noninvasive tests which can safely predict DU in adult men. Methods Unselected, treatment-naïve male patients aged ≥40 years with uncomplicated, non-neurogenic LUTS were prospectively evaluated. All men received—after standard assessment of male LUTS–ultrasound detrusor wall thickness (DWT) measurements at a bladder filling ≥250 ml and computer urodynamic investigation. DU was defined as incomplete bladder emptying (>30 ml) in the absence of bladder outlet obstruction or dysfunctional voiding. Classification and regression tree (CART) analysis was used to determine parameters and threshold values for DU. Results The study population consisted of 143 consecutive men with medians of 62 years, IPSS 16, and prostate volume 35 ml. In total, 33 patients (23.1 %) had DU. CART analysis showed that all men with DWT ≤ 1.23 mm plus bladder capacity >445 ml had DU. This multivariate model has a sensitivity of 42 %, specificity of 100 %, positive predictive value of 100 %, and negative predictive value of 85 %. Conclusions This study showed that all men with ultrasound DWT ≤ 1.23 mm + bladder capacity >445 ml have DU. Combination of these two tests could help physicians to diagnose DU noninvasively in clinical practice. A prospective independent study should confirm these results.
- 16 December 2015
- Published by Springer Nature in Der Urologe
- Vol. 55 (1) , 81-96
Medikamentöse Therapie des benignen Prostatasyndroms
Die medikamentöse Therapie des benignen Prostatasyndroms (BPS) ist bei Vorliegen von LUTS („lower urinary tract symptoms“) mit Leidensdruck sowie bei Abwesenheit von absoluten Operationsindikationen oder ausgeprägter Obstruktion indiziert. Phytopharmaka können bei milder bis moderater Symptomatik eingesetzt werden. Alphablocker reduzieren schnell und effektiv LUTS und die symptomatische Krankheitsprogression. Phosphodiesterase-Typ-5-Inhibitoren (PDE5-I) sind eine Therapiealternative zu Alphablockern, wenn Männer unter letzteren Nebenwirkungen oder eine erektile Dysfunktion zeigen. Bei Blasenspeichersymptomen und kleiner Prostata kann ein Antimuskarinikum ebenfalls effektiv LUTS vermindern. Der kombinierte Einsatz von Alphablocker plus Antimuskarinikum ist bei der Behandlung von LUTS effektiver als die Einzelsubstanzen. 5α-Reduktase-Inhibitoren (5ARI) können bei großer Prostata (> 30–40 ml) LUTS sowie die Wahrscheinlichkeit eines Harnverhalts bzw. die Notwendigkeit einer Prostataoperation signifikant vermindern. Die Kombination aus 5ARI plus Alphablocker ist bei der Reduktion von LUTS und Verhinderung der Krankheitsprogression effektiver als die Einzelsubstanzen. Die Kombinationstherapie aus PDE5-I (Tadalafil) plus 5ARI (Finasterid) reduziert LUTS signifikant stärker als 5ARI allein. PDE5-I verhindern die sexuellen Nebenwirkungen einer 5ARI-Therapie.
- 16 December 2015
- Published by Springer Nature in Der Urologe
- Vol. 55 (1) , 81-96
Medikamentöse Therapie des benignen Prostatasyndroms
Die medikamentöse Therapie des benignen Prostatasyndroms (BPS) ist bei Vorliegen von LUTS („lower urinary tract symptoms“) mit Leidensdruck sowie bei Abwesenheit von absoluten Operationsindikationen oder ausgeprägter Obstruktion indiziert. Phytopharmaka können bei milder bis moderater Symptomatik eingesetzt werden. Alphablocker reduzieren schnell und effektiv LUTS und die symptomatische Krankheitsprogression. Phosphodiesterase-Typ-5-Inhibitoren (PDE5-I) sind eine Therapiealternative zu Alphablockern, wenn Männer unter letzteren Nebenwirkungen oder eine erektile Dysfunktion zeigen. Bei Blasenspeichersymptomen und kleiner Prostata kann ein Antimuskarinikum ebenfalls effektiv LUTS vermindern. Der kombinierte Einsatz von Alphablocker plus Antimuskarinikum ist bei der Behandlung von LUTS effektiver als die Einzelsubstanzen. 5α-Reduktase-Inhibitoren (5ARI) können bei großer Prostata (> 30–40 ml) LUTS sowie die Wahrscheinlichkeit eines Harnverhalts bzw. die Notwendigkeit einer Prostataoperation signifikant vermindern. Die Kombination aus 5ARI plus Alphablocker ist bei der Reduktion von LUTS und Verhinderung der Krankheitsprogression effektiver als die Einzelsubstanzen. Die Kombinationstherapie aus PDE5-I (Tadalafil) plus 5ARI (Finasterid) reduziert LUTS signifikant stärker als 5ARI allein. PDE5-I verhindern die sexuellen Nebenwirkungen einer 5ARI-Therapie.
- 24 August 2015
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 69 (12) , 1496-1507
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an
Purpose The influence of cardiovascular risk factors/comorbidities on response to oral once‐daily tadalafil 5 mg was explored in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Methods This post hoc analysis pooled data from four double‐blind studies in which 1498 men with > 6‐mo history of LUTS/BPH were randomised and received either once‐daily placebo (n = 746) or tadalafil 5 mg (n = 752) for 12 weeks. Descriptive statistics were reported for changes in total International Prostate Symptom Score (IPSS), IPSS voiding and storage subscores, and IPSS quality‐of‐life (QoL) index. Treatment group differences by baseline clinical and cardiovascular factors and medical therapies were examined using analysis of covariance. Results Tadalafil was effective in men with LUTS/BPH and cardiovascular risk factors/comorbidities except for patients receiving > 1 antihypertensive medication. Placebo‐adjusted least squares (LS) mean improvements in total IPSS were −1.2 (95% CI: −2.5 to −0.0) in men taking > 1 antihypertensive medication vs. −3.3 (95% CI: −4.4 to −2.1) in men taking one medication (interaction p = 0.020). In addition, placebo‐adjusted LS mean improvements in total IPSS were −0.2 (95% CI, −2.1 to 1.7) in men who reported use of diuretics vs. −2.8 (95% CI, −3.7 to −1.9) in men who reported taking other antihypertensive medications vs. −2.3 (95% CI, −3.2 to −1.5) in men who reported not using any antihypertensive drug (p‐value for interaction = 0.053). Conclusions Once‐daily tadalafil 5 mg improved LUTS/BPH, regardless of severity, in men with coexisting cardiovascular risk factors/comorbidities, except for patients with history of > 1 drug for arterial hypertension. Use of diuretics may contribute to patients’ perception of a negated efficacy of tadalafil on LUTS/BPH. Comorbidities should be considered when choosing the optimal medicine to treat men with LUTS/BPH.
- 24 August 2015
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 69 (12) , 1496-1507
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an
Purpose The influence of cardiovascular risk factors/comorbidities on response to oral once‐daily tadalafil 5 mg was explored in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Methods This post hoc analysis pooled data from four double‐blind studies in which 1498 men with > 6‐mo history of LUTS/BPH were randomised and received either once‐daily placebo (n = 746) or tadalafil 5 mg (n = 752) for 12 weeks. Descriptive statistics were reported for changes in total International Prostate Symptom Score (IPSS), IPSS voiding and storage subscores, and IPSS quality‐of‐life (QoL) index. Treatment group differences by baseline clinical and cardiovascular factors and medical therapies were examined using analysis of covariance. Results Tadalafil was effective in men with LUTS/BPH and cardiovascular risk factors/comorbidities except for patients receiving > 1 antihypertensive medication. Placebo‐adjusted least squares (LS) mean improvements in total IPSS were −1.2 (95% CI: −2.5 to −0.0) in men taking > 1 antihypertensive medication vs. −3.3 (95% CI: −4.4 to −2.1) in men taking one medication (interaction p = 0.020). In addition, placebo‐adjusted LS mean improvements in total IPSS were −0.2 (95% CI, −2.1 to 1.7) in men who reported use of diuretics vs. −2.8 (95% CI, −3.7 to −1.9) in men who reported taking other antihypertensive medications vs. −2.3 (95% CI, −3.2 to −1.5) in men who reported not using any antihypertensive drug (p‐value for interaction = 0.053). Conclusions Once‐daily tadalafil 5 mg improved LUTS/BPH, regardless of severity, in men with coexisting cardiovascular risk factors/comorbidities, except for patients with history of > 1 drug for arterial hypertension. Use of diuretics may contribute to patients’ perception of a negated efficacy of tadalafil on LUTS/BPH. Comorbidities should be considered when choosing the optimal medicine to treat men with LUTS/BPH.
- 31 July 2015
- Published by Wiley in Neurourology and Urodynamics
- Vol. 35 (8) , 980-986
Unravelling detrusor underactivity: Development of a bladder outlet resistance—Bladder contractility nomogram for adult male patients with lower urinary tract symptoms
Aims: Voiding dysfunction in adult men may be caused by bladder outlet obstruction (BOO) and/or detrusor underactivity (DU). Until now, it is only possible to classify BOO and DU by pressure‐flow analysis. Low values of the maximum Watts factor (Wmax) indicate DU but thresholds for the diagnosis have not been established. Purpose of this study was to construct a nomogram using bladder outlet resistance and detrusor contractility in order to classify BOO and DU simultaneously.Methods: Treatment naïve men aged ≥40 years with uncomplicated lower urinary tract symptoms (LUTS) were prospectively evaluated. Patients were assessed with IPSS, prostate volume, uroflowmetry, post‐void residual, and pressure‐flow measurement. The bladder outlet obstruction index (BOOI) was used to determine BOO‐grade and Wmax to calculate detrusor contractility. Individual BOOI‐Wmax values were plotted in a graph. Linear interpolation was applied to determine the 10th, 25th, 50th, 75th, and 90th percentiles.Results: Retrospective analysis of 822 male patients with means of 64 years, IPSS 16, and prostate volume of 40 cc. Patient and clinical parameters of the P = 0.006), bladder capacity (503 vs. 442 ml, P = 0.009), post‐void residual urine (167 vs. 116 ml, P = 0.001), and voiding efficiency (67% vs. 73%, P = 0.015).Conclusions: The nomogram quantifies the relationship between detrusor contractility and BOO in men with LUTS. A measurement value Neurourol. Urodynam. 35:980–986, 2016.
- 31 July 2015
- Published by Wiley in Neurourology and Urodynamics
- Vol. 35 (8) , 980-986
Unravelling detrusor underactivity: Development of a bladder outlet resistance—Bladder contractility nomogram for adult male patients with lower urinary tract symptoms
Aims: Voiding dysfunction in adult men may be caused by bladder outlet obstruction (BOO) and/or detrusor underactivity (DU). Until now, it is only possible to classify BOO and DU by pressure‐flow analysis. Low values of the maximum Watts factor (Wmax) indicate DU but thresholds for the diagnosis have not been established. Purpose of this study was to construct a nomogram using bladder outlet resistance and detrusor contractility in order to classify BOO and DU simultaneously.Methods: Treatment naïve men aged ≥40 years with uncomplicated lower urinary tract symptoms (LUTS) were prospectively evaluated. Patients were assessed with IPSS, prostate volume, uroflowmetry, post‐void residual, and pressure‐flow measurement. The bladder outlet obstruction index (BOOI) was used to determine BOO‐grade and Wmax to calculate detrusor contractility. Individual BOOI‐Wmax values were plotted in a graph. Linear interpolation was applied to determine the 10th, 25th, 50th, 75th, and 90th percentiles.Results: Retrospective analysis of 822 male patients with means of 64 years, IPSS 16, and prostate volume of 40 cc. Patient and clinical parameters of the P = 0.006), bladder capacity (503 vs. 442 ml, P = 0.009), post‐void residual urine (167 vs. 116 ml, P = 0.001), and voiding efficiency (67% vs. 73%, P = 0.015).Conclusions: The nomogram quantifies the relationship between detrusor contractility and BOO in men with LUTS. A measurement value Neurourol. Urodynam. 35:980–986, 2016.
- Open Access
- 7 July 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 65
Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study
Radiotherapy is one of the treatment options for prostate cancer (PCa) but up to 25 % of men report about severe nocturia (nocturnal voiding). The combination of hyaluronic acid (HA) and chondroitin sulfate (CS) resembles glycosaminoglycan (GAG) replenishment therapy. The aim of our study was to evaluate the impact of HA and CS on nocturia, in men with nocturia after PCa radiotherapy. Twenty-three consecutive patients with symptomatic cystitis after external radiotherapy for PCa were enrolled. Patients underwent bladder instillation therapy with HA and CS weekly for the first month and, afterwards, on week 6, 8 and 12. Nocturnal voiding frequency was assessed by item 3 (Q3) of the Interstitial Cystitis Symptoms Index (ICSI) and item 2 (Q2) of the Interstitial Cystitis Problem Index (ICPI). Data were analyzed with paired-samples T-test and adjusted for age. Eighteen patients (78 %) reported about nocturia. Pre- and post-treatment ICSI-Q3 was 2.13 ± 0.28 and 1.61 ± 0.21 (−24.4 %, p = 0.001). With logistic regression analysis, both age and baseline ICSI-Q3 had a significant impact on nocturnal voiding frequency (r = 0.293, p = 0.011 and r = 0.970, p < 0.001). Pre- and post-treatment ICPI-Q2 was 1.87 ± 0.26 and 1.30 ± 0.25 (−30.5 %, p = 0.016); logistic regression analysis was without significant findings. Bladder instillation treatment with a combination of HA and CS was effective in reducing nocturnal voiding frequency in men with post-radiation bladder pain for PCa. Randomized, controlled trials with sham treatment are needed to confirm our result.
- 7 July 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 65
Open AccessSodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study
Radiotherapy is one of the treatment options for prostate cancer (PCa) but up to 25 % of men report about severe nocturia (nocturnal voiding). The combination of hyaluronic acid (HA) and chondroitin sulfate (CS) resembles glycosaminoglycan (GAG) replenishment therapy. The aim of our study was to evaluate the impact of HA and CS on nocturia, in men with nocturia after PCa radiotherapy. Twenty-three consecutive patients with symptomatic cystitis after external radiotherapy for PCa were enrolled. Patients underwent bladder instillation therapy with HA and CS weekly for the first month and, afterwards, on week 6, 8 and 12. Nocturnal voiding frequency was assessed by item 3 (Q3) of the Interstitial Cystitis Symptoms Index (ICSI) and item 2 (Q2) of the Interstitial Cystitis Problem Index (ICPI). Data were analyzed with paired-samples T-test and adjusted for age. Eighteen patients (78 %) reported about nocturia. Pre- and post-treatment ICSI-Q3 was 2.13 ± 0.28 and 1.61 ± 0.21 (−24.4 %, p = 0.001). With logistic regression analysis, both age and baseline ICSI-Q3 had a significant impact on nocturnal voiding frequency (r = 0.293, p = 0.011 and r = 0.970, p < 0.001). Pre- and post-treatment ICPI-Q2 was 1.87 ± 0.26 and 1.30 ± 0.25 (−30.5 %, p = 0.016); logistic regression analysis was without significant findings. Bladder instillation treatment with a combination of HA and CS was effective in reducing nocturnal voiding frequency in men with post-radiation bladder pain for PCa. Randomized, controlled trials with sham treatment are needed to confirm our result.
- 24 February 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 35 (S1) , 3-6
Latest Developments in the Assessment and Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: What is Clinically Relevant?
- 24 February 2015
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 35 (S1) , 3-6
Latest Developments in the Assessment and Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: What is Clinically Relevant?